Cancer in France

CLARA DAY ON
OPERATIONS RESEARCH IN
CANCER TREATMENT &
OPERATION MANAGEMENT
November 17, 2010
S
SP
PE
EE
ED
D II N
NG
G U
UP
P P
PR
RO
OG
GR
RE
ES
SS
S
Under
aegis of
of the
theBullukian
BullukianFoundation
Foundation
Under the
the aegis
Seven Cancer Research Networks
within France
Cancer in France
Incidence
315,000 / year
Mortality
150,000 / year
• To facilitate
and
coordinate
Cancer research,
in particular
Translational Research.
• Coordination by French National
Cancer Institute (INCa).
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P2
CLARA: research network organization
European and international dimension
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P3
CLARA goals
Rapid transfer
of research to patients
Economic development
of oncology research
Translational
Cancer Research
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P4
CLARA major partners
with international leadership position
CEA-Leti : Atomic
Energy Commission –
Electronic and Information
Technology Laboratory
GENEVA
CERN
CERN: European
Organization for Nuclear
Research
CRMN: European Center
for High Field NMR
ELI : European
Lymphoma Institute
IARC: International
Agency for Research on
Cancer
ELuI: European Lung
Institute
PARCC-ARA: Support
Platform for Clinical
Research in Oncology in
the inter-region RhôneAlpes Auvergne
LYON
CRMN
ELI
IARC
PARCC
WSN
GRENOBLE
CEA-Leti
ELuI
WSN: World Sarcoma
Network
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P5
CLARA major Cancer pathologies with
international leadership position
1st
order
2nd
order
Lymphoma
Sarcoma
Lung
Glioblastoma
Hepatocarcinoma
ELI
Pr Coiffier – Pr Salles
WSN
Pr Blay
LCEH Pr Brambilla
Pr Honnorat – Pr Berger
Pr Trepo, Pr Zoulim,
Pr Merle
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P6
CLARA’s whole spectrum
of competitive platforms
Clinical research
Hadrontherapy
Bio therapies
Cancer prevention
Cancer epidemiology
Patient bed site
Imaging facilities
Experimental cancer models
Bio informatics
Nanotechnologies
Pharmacogenomics
Metabolomics
Proteomics
€ 50M
investment
Genomics - Epigenomics
Lab bench
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P7
European Observatory of Cancer
http://eu-cancer.iarc.fr/
Data about Europe
France
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P8
CLARA Strengths and Key Features
Unique integrated research network focused on
oncology in Rhône-Alpes-Auvergne
Brings out, evaluates and assists R&D projects
involving interdisciplinary experts at the academic,
clinical and private companies level
Flexible, reactive and significant funding thanks to
the support of INCa, local authorities, and European
funds making possible both the CLARA “Proof of
concept” programme and CLARA core projects
Neutral and independent interface towards private
investors and research organisations
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P9
CLARA auto-analysis 2007-2010
STRONG POINTS
Significant contribution of CLARA researchers to high-impact
journals
Five IBiSA national certifications have been granted to
CLARA platforms and three major biological resources
centres have been certificated
CLARA Portfolio of 25 Proof of concept projects (€32M) based
on academic-clinical-industrial cooperation
Initiation of first class projects for enhanced visibility and
attractiveness of research
CLARA mobilises diversified funding resources
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 10
INCa-funded projects
INCa 2009 Activity Report
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 11
Synopsis of bibliometric analysis
Quantitative evolution of publications
Progression index
(2005 as 100%)
140%
130%
World
France
120%
CLARA
110%
100%
2005
2006
2007
2008
2009
year
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 12
Synopsis of bibliometric analysis
Cancéropôles contribution to international
visibility
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 13
CLARA’s Proof of Concept programme
Growth of CLARA projects portfolio
Number of projects
30
25
20
Completed with Proof of Concept
15
Completed
10
Ongoing
5
0
2005 2006 2007 2008 2009 2010
Year
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 14
CLARA PoC economical impact
The projects have generated a variety of economic spillovers. 18
start-ups and SMEs have invested €22 M (versus €10M by
CLARA), and 11 companies have reached significant “growth
milestones”:
5 start-ups have been created: iDD Biotech, Ecrin
Therapeutics, Fluoptics, Netris Pharma and Synthelis,
1 foreign company subsidiary establishment in the region :
OncoTherapy Science from Japan,
5 companies raised capital (>€40M) : EDAP TMS, EndoControl
Medical, ERYtech Pharma, ImmunID Technologies and
Nanobiotix,
4 companies are listed on the stock exchange or trade sale:
EDAP TMS, Genome Express, Innate Pharma (IPO) and OPi.
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 15
CLARA scientific events
 CLARA organised event  co-organised with another Cancéropôle
Organisation des soins en cancérologie, 17 novembre 2010
Sous l'égide de la Fondation Bullukian
P 16
Priorities for 2011-2014
Further mobilise its network on two priorities:
identification and assistance to projects of academic –
clinical – industrial partnerships in the field of cancer
Develop synergies with key regional partners and
abroad in the frame of project detection, evaluation,
maturing and funding
Reinforce communication on its strategy, projects and
results, especially on the Cancéropôle CLARA’s “Proof
of Concept” programme
Gain further financial support from INCa, regional
authorities, French programmes and European funds
to support ambitious projects
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 17
Work plan
Transverse
actions
Technological
platforms and
biological
resources
centres
Support to
Clinical
Research
Proof of
concept
Axis I: “Tumour escape, cell plasticity and targeted therapy”
Priority
axes
Axis II: “Infections and Cancer”
Axis III: “Nanotechnology, imaging and cancer”
Axis A: “Evaluation, risk perception and cancer prevention”
Emerging
axes
Axis B: “Environment, nutrition and cancer”
Axis C: “Hadrontherapy and cancer”
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 18
CLARA Ambition for 2014
Expand the CLARA Proof of Concept programme in
oncology to other European regions
A significant move within its projects from pre-clinical
studies to clinical trials
An increased participation of CLARA teams to
European programmes and ambitious initiatives
An acceleration of company creations, development
and arrival in the region
A broad-spectrum network of experts providing
services to oncology research and patients
A clear visibility of CLARA’s research within the
nation and elsewhere in Europe
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 19
Support to Clinical Research
PHRC cancer
Clinical
PARCC-ARA
platform
Data management
Information
Training
Support to
CLARA’s major
cancer
pathologies
European Lymphoma Institute (ELI)
World Sarcoma Network (WSN)
European Lung Institute (ELuI)
In support of Measure 4, Cancer Plan II to stimulate clinical research
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 20
Project of Evaluation, Risk Perception and
Cancer Prevention
Links
Primary prevention
Identification of risk factors
Patients’ perception of risks
Prevention
Axis B
Screening
Evaluation of screening programmes
Determinants of participation to screening programmes
Targeted interventions in non-participative population
Axis III
Collective / individual decision-making
Therapeutic
management
Quantitative analysis
Qualitative analysis
Therapeutic management optimisation
Homecare
Patients education programmes
•In support of Measure 2, Cancer Plan II to understand through research and
reduce inequalities in relation to cancer
•With support of the interregional Regional Resources Centre for Information,
Prevention and Education about Cancers (Hygée centre, St-Etienne)
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 21
Project of Evaluation, Risk Perception and
Cancer Prevention
Prevention
Patients
involvement
Health
inequalities
 Education of intermediaries for
cancer mass screening in nonprivileged areas
 Reasons for either
participating or not to cancer
mass screening
Health inequalities for breast
and colon cancer screening
Therapeutic
management
Develop a multidisciplinary approach
Study the role and consequences of
inequalities rather than their description
 Participate to the development of
methods to evaluate interventions to
reduce health inequalities
 Economic study on adherence
to clinical practice in sarcoma
 Determinants of therapeutic
management for patients with
broncho-pulmonar cancer
 Evaluation of therapeutic
management of hospital vs. home
chemotherapy
Organisation des soins en cancérologie, 17 novembre 2010
Optimum mapping of various
organisational methods according
to geographical, epidemiological
and demographic situations
Under the aegis of the Bullukian Foundation
P 22
Thanks to our partners
Organisation des soins en cancérologie, 17 novembre 2010
Under the aegis of the Bullukian Foundation
P 23